WITH ULORIC 80 MG — SUPERIOR TO ALLOPURINOL AT LOWERING sUA TO <6 MG/DL IN GOUT PATIENTS WITH CKD THROUGH STAGE 34*
ESTABLISHED SAFETY PROFILE4,5
ULORIC is not indicated to treat CKD.4
The dose of ULORIC is limited to 40 mg once daily in patients with CKD stage 4.4
ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ULORIC is not recommended for the treatment of asymptomatic hyperuricemia.
CKD=chronic kidney disease; sUA=serum uric acid.
*Mild renal impairment (CKD stage 2) is defined as estimated glomerular filtration rate (eGFR) 60-89 mL/min/1.73 m2; moderate renal impairment (CKD stage 3) is defined as eGFR 30-59 mL/min/1.73 m2; severe renal impairment (CKD stage 4) is defined as eGFR 15-29 mL/min/1.73 m2.1